Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...

Sanofi (SNY) has received Chinese regulatory approval for two rare hematology drugs, Qfitlia and Cablivi, significantly ...

Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.

The National Medical Products Administration in China has approved two Sanofi (SNY) medicines for rare hematologic diseases: Qfitlia for ...

With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...

Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...

Investing.com -- Sanofi has received approval for two bleeding disorder treatments in China, expanding its hematology portfolio in the country. The French pharmaceutical company announced Thursday ...

Sanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the antithrombin-lowering therapy is indicated for use as a prophylactic treatment ...

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...